Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126464291 | 12646429 | 1 | I | 20160728 | 20160812 | 20160812 | EXP | US-CIPLA LTD.-2016US17166 | CIPLA | 0.00 | Y | 0.00000 | 20160812 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126464291 | 12646429 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 400 MG, QD | U | U | 90705 | 400 | MG | CAPSULE | QD | ||||
| 126464291 | 12646429 | 2 | C | NEURONTIN | GABAPENTIN | 1 | Unknown | UNK, FOR 15 YEARS | U | U | 0 | CAPSULE |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126464291 | 12646429 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126464291 | 12646429 | Body height decreased | |
| 126464291 | 12646429 | Drug intolerance | |
| 126464291 | 12646429 | Pain | |
| 126464291 | 12646429 | Product substitution issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126464291 | 12646429 | 1 | 201601 | 0 |